Research Topics
| G JacksonSummaryCountry: UK Publications
| Collaborators
|
Detail Information
Publications
Erectile dysfunction and coronary disease: evaluating the linkGraham Jackson
Guy s and St Thomas Hospitals NHS Trust, United Kingdom
Maturitas 72:263-4. 2012..Its treatment is often successful, maintaining quality of life in the middle aged and elderly. ED should always be queried as part of the ongoing health care worker and patient relationship - its early detection may prevent early death...
Assessing the problem of counterfeit medications in the United KingdomG Jackson
Cardiac Department, St Thomas Hospital, London, UK
Int J Clin Pract 66:241-50. 2012....
Prevention of cardiovascular disease by the early identification of erectile dysfunctionG Jackson
Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
Int J Impot Res 20:S9-14. 2008..This article discusses the rationale for the link between ED and CAD, with reference to endothelial dysfunction, and the role of ED as an important means of identifying men at risk of vascular disease...
Hemodynamic and exercise effects of phosphodiesterase 5 inhibitorsGraham Jackson
Cardiothoracic Centre, St Thomas Hospital, London, UK
Am J Cardiol 96:32M-36M. 2005....
Gender differences in cardiovascular disease preventionGraham Jackson
Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
Menopause Int 14:13-7. 2008....
Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensusG Jackson
Cardiology, London Bridge Hospital, London, UK
Int J Clin Pract 64:848-57. 2010..Review of cardiovascular status and response to ED therapy should be performed at regular intervals (Level 1, Grade A)...
Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse eventsGraham Jackson
Guy s and St Thomas Hospital, London, UK
J Sex Med 1:161-7. 2004..Cardiovascular disease and erectile dysfunction (ED) share similar risk factors and often occur concomitantly. Therefore, men with ED may be at increased risk for cardiovascular adverse events...
Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risksG Jackson
Cardiac Department, St Thomas Hospital, London, UK
Int J Clin Pract 64:497-504. 2010..The worldwide nature of the counterfeit problem requires proper coordination between countries to ensure adequate enforcement. Locally, physicians who treat ED need to inform patients of the dangers of ordering PDE5is via the Internet...
Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunctionGraham Jackson
Guy s and St Thomas Hospital Cardiothoracic Centre, London, United Kingdom
J Sex Med 2:513-6. 2005..Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction...
The importance of risk factor reduction in erectile dysfunctionGraham Jackson
Cardiothoracic Centre, 6th Floor, East Wing, St Thomas Hospital, Lambeth Palace Road, London, SE1 7EH, United Kingdom
Curr Urol Rep 8:463-6. 2007..Though phosphodiesterase type 5 inhibitors are highly effective in treating ED, lifestyle advice and aggressive risk reduction remain fundamental to the overall vascular good health of the individual...
Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunctionGraham Jackson
St Thomas Hospital, London, UK
J Sex Med 2:407-14. 2005..Mild hemodynamic effects have been reported with sildenafil citrate therapy...
The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicineGraham Jackson
Cardiothoracic Center, St Thomas Hospital, London, UK
J Sex Med 3:28-36; discussion 36. 2006..The first Princeton Consensus Conference (Princeton I) in 1999 developed guidelines for safe management of cardiac patients regarding sexual activity and the treatment of ED...
Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selectionGraham Jackson
St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
Drugs 64:1533-45. 2004..Addressing ED in patients with cardiovascular disease can lead to a substantial improvement in quality of life and success is not difficult to achieve...
Cardiovascular safety of sildenafil citrate (Viagra): an updated perspectiveGraham Jackson
St Thomas Hospital, London, United Kingdom
Urology 68:47-60. 2006..Management recommendations based on cardiovascular risk, from the Second Princeton Consensus Conference, are presented...
Erectile dysfunction and silent coronary artery disease: abnormal computed tomography coronary angiogram in the presence of normal exercise ECGsG Jackson
Cardiothoracic Centre, Guy s and St Thomas NHS Hospital Trust, St Thomas Hospital, London, UK
Int J Clin Pract 62:973-6. 2008..Exercise electrocardiography may identify flow-limiting CAD but cardiac computed tomography (CT) may identify early non-calcified plaque disease potentially vulnerable to rupture precipitating an acute event...
Cardiovascular aspects of sexual medicineGraham Jackson
Guy s and St Thomas Hospitals NHS Trust, Cardiology, London, UK
J Sex Med 7:1608-26. 2010..Erectile dysfunction (ED) is common and considered to be predominantly of vascular origin...
Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performanceH A Walker
Cardiothoracic Centre, St. Thomas' Hospital, London, United Kingdom
J Am Coll Cardiol 38:499-505. 2001....
A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement--update 2002G Jackson
Cardiothoracic Centre, St Thomas' Hospital, London, UK
Int J Clin Pract 56:663-71. 2002..The pro-active management of ED in the cardiovascular patient provides an ideal and effective opportunity to address other cardiovascular risk factors and improve treatment outcomes...
Cardiovascular risk factors determine erectile and arterial function response to sildenafilHemant Solomon
Department of Cardiology, Cardiothoracic Centre, St. Thomas' Hospital, London, United Kingdom
Am J Hypertens 19:915-9. 2006..Improved cardiovascular risk factor control is likely to increase the efficacy of phosphodiesterase-5 inhibitor therapy in the treatment of erectile dysfunction...
Is erectile dysfunction a marker for cardiovascular disease?M Kirby
Department of Cardiology, Guy s Hospital, London, UK
Int J Clin Pract 55:614-8. 2001..Unrestricted NHS availability of ED treatments such as sildenafil could facilitate greater achievement of National Service Framework targets for coronary heart disease...
Past, present, and future: a 7-year update of Viagra (sildenafil citrate)G Jackson
Guys and St Thomas Hospital Trust, London, UK
Int J Clin Pract 59:680-91. 2005..Special emphasis is placed on the impact of sildenafil on our understanding of sexual health and on the extensive safety and efficacy data that have been amassed from numerous clinical trials...
Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease?G W Lloyd
The Cardiothoracic Centre, St Thomas Hospital, London, UK
Heart 84:189-92. 2000..To determine whether angina in women with established coronary heart disease varies with changes in hormone concentrations during the menstrual cycle...
Erectile dysfunction: cardiovascular risk and the role of the cardiologistH Solomon
Department of Cardiology, St Thomas' Hospital, London, UK
Int J Clin Pract 57:96-9. 2003..ED is associated with a high incidence of occult cardiovascular disease. We suggest that cardiologists can significantly contribute to the management of ED...
A qualitative study investigating patients' beliefs about cardiac rehabilitationA F Cooper
Cardiothoracic Centre, St Thomas Hospital, London, UK
Clin Rehabil 19:87-96. 2005..The opportunity to attend a cardiac rehabilitation course is usually offered to patients who have suffered a myocardial infarction. However, despite referral, many patients fail to attend...
Phosphodiesterase 5 inhibition: effects on the coronary vasculatureG Jackson
Cardiac Department, St Thomas' Hospital, London SE1 7EH, UK
Int J Clin Pract 55:183-8. 2001..Together with findings from other studies, these data suggest that PDE5 may play an important role in the regulation of coronary blood flow in the healthy and diseased heart...
Sexual dysfunction and diabetesG Jackson
Cardiothoracic Centre, St Thomas Hospital, London, UK
Int J Clin Pract 58:358-62. 2004..Problems with arousal, lubrication and orgasmic dysfunction occur, but the fatigue of diabetes may be influencing these complaints, and in general, psychological issues appear to predominate...
Assessing patients' beliefs about cardiac rehabilitation as a basis for predicting attendance after acute myocardial infarctionA F Cooper
Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
Heart 93:53-8. 2007....
Viagra on the internet: unsafe sexual practiceH Solomon
Department of Cardiology, Guy's and St. Thomas' Hospital, London, UK
Int J Clin Pract 56:403-4. 2002..In this case report we highlight that ED itself is a risk factor for occult CHD and illustrate the need for careful medical assessment and adherence to published guidelines for the management of ED...
Smoking cessation: a consensus statement with special reference to primary careG Jackson
Cardiothoracic Centre, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
Int J Clin Pract 55:385-92. 2001..Smoking cessation is one of the most cost-effective healthcare interventions that can be made...
Factors associated with cardiac rehabilitation attendance: a systematic review of the literatureA F Cooper
Cardiothoracic Centre, 6th Floor, East Wing, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
Clin Rehabil 16:541-52. 2002..Many eligible patients fail to attend cardiac rehabilitation courses...
Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominatorH Solomon
Department of Cardiology, 6th Floor, East Wing, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
Heart 89:251-3. 2003..Cardiovascular risk stratification is an important initial step in managing such patients. In cardiac patients considered to have low cardiovascular risk, the management of ED can be safe and effective...
Erectile dysfunction and statin treatment in high cardiovascular risk patientsH Solomon
Department of Cardiology, Cardiothoracic Centre, St. Thomas' Hospital, Lambeth Palace Road, London, UK
Int J Clin Pract 60:141-5. 2006..This study suggests ED following statin therapy is more likely in patients with severe endothelial dysfunction due to established cardiovascular risk factors including age, smoking and diabetes...
Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunctionAnthony S Wierzbicki
Department of Chemical Pathology, St Thomas Hospital Lambeth Palace Road, London SE1 7EH, UK
Atherosclerosis 185:421-5. 2006..Erectile dysfunction is related to penile arterial endothelial nitric oxide production. Asymmetric dimethylarginine (ADMA) and E-selectin are often considered plasma markers of endothelial function...
Sexual response in cardiovascular diseaseGraham Jackson
London Bridge Hospital, London, England
J Sex Res 46:233-6. 2009..As erectile dysfunction in men over 40 years of age is usually of vascular (endothelial dysfunction) origin, they should be considered "cardiovascular equivalents," and secondary prevention guidelines should be followed...
Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefitG Jackson
Cardiothoracic Centre, St Thomas' Hospital, London, UK
Int J Clin Pract 56:397-8. 2002..Sildenafil acting as a phosphodiesterase 5 inhibitor may have an important role to play in the management of PPH and we believe further study to be of importance...
Haemodynamic and metabolic agents in the treatment of stable angina: publication reviewG Jackson
Guy s and St Thomas Hospitals, NHS Trust, Cardiothoracic Centre, London, UK
Coron Artery Dis 12:S22-4. 2001..Patients who fail to respond to optimal haemodynamic and metabolic therapy should be considered for a revascularisation procedure, not random additional drug therapy...
The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trialG W Lloyd
Guys and St Thomas Hospital Trust, Lambeth Palace Road, London SE1 7EH, UK
Atherosclerosis 158:445-54. 2001....
Risk factor management: the cardiologist's perspectiveG Jackson
Guy s Hospital, London, UK
Br J Clin Pract Suppl 77:33-9. 1996..The patient is a victim of poor investment in prevention, while the cardiologist is put off by a perceived lack of balance from the medical protagonists...
Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agentsG Jackson
Cardiothoracic Centre, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
Int J Clin Pract 55:256-61. 2001..It is suggested that combination haemodynamic and metabolic therapy is a logical new approach to patients whose angina is inadequately controlled despite optimal haemodynamic therapy...
Erectile dysfunction: is there silent obstructive coronary artery disease?P D O'Kane
Cardiothoracic Centre, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
Int J Clin Pract 55:219-20. 2001..The presence of silent co-existing myocardial ischaemia should be considered in men who present with ED, particularly when they have other cardiovascular risk factors...
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective surveyN Salooja
Department of Haematology, Imperial College of Science and Medicine, Hammersmith Hospital, London, UK
Lancet 358:271-6. 2001..INTERPRETATION: Pregnancy after SCT is likely to have a successful outcome. Pregnancies in allograft patients who have received total body irradiation should be treated as high risk for maternal and fetal complications...
The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiolH A Walker
Cardiothoracic Centre, St Thomas' Hospital, London, UK
Circulation 103:258-62. 2001..CONCLUSIONS: Genistein causes L-arginine/NO-dependent vasodilation in forearm vasculature of human subjects with similar potency to 17beta-estradiol and potentiates endothelium-dependent vasodilation to acetylcholine...
Biologic therapies for juvenile arthritisN Wilkinson
Department of Rheumatology, Great Ormond Street Hospital, London, UK
Arch Dis Child 88:186-91. 2003..However, as will also be discussed, overlap of pathways within a complex immune system makes clinical response unpredictable and raises additional ethical and administrative concerns...
Guidelines on the management of acute myeloid leukaemia in adultsD W Milligan
British Society for Haematology, London, UK
Br J Haematol 135:450-74. 2006
Making PROGRESS in stable patients post stroke or transient ischaemic attack: implications for general practiceG Jackson
Cardiothoracic Centre, St Thomas' Hospital, London, UK
Int J Clin Pract 57:385-7. 2003..g. aspirin, statins). Therapy can be initiated and monitored either from hospital outpatients or general practice or both in co-operation...
Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteinePeter D O'Kane
Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, London, UK
Atherosclerosis 196:574-9. 2008..As a secondary aim, we wished to ascertain whether whole body NO biosynthesis is inversely related to plasma homocysteine (Hcy) levels...
Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatmentLindsay R Queen
Department of Cardiology, Cardiothoracic Centre, St Thomas' Hospital, London, UK
Cardiovasc Res 59:152-9. 2003..This indicates that aspirin exerts divergent effects on basal and beta-AR-stimulated platelet NOS activity, which are likely to be of clinical relevance...
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)John B Kostis
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
Am J Cardiol 96:85M-93M. 2005..Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended...
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover studyIan Eardley
Pyrah Department of Urology, St James University Hospital, Becket Street, Leeds, UK
BJU Int 100:122-9. 2007....
Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosingRobert A Kloner
The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Am J Cardiol 97:1778-84. 2006..In this clinical trial population of men with erectile dysfunction, tadalafil was not associated with an increased risk for serious cardiovascular adverse events...
Vascular risk factors and erectile dysfunction: 'sexing-up' the importance of lifestyle changesGraham Jackson
Int J Clin Pract 61:1421-2. 2007
The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines, new challengesGraham Jackson
Int J Clin Pract 60:127. 2006
Erectile dysfunction and cardiac disease: recommendations of the Second Princeton ConferenceRaymond C Rosen
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08854, USA
Curr Urol Rep 7:490-6. 2006..Other drug interactions and the cardiovascular safety of testosterone replacement therapy are considered...
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)John B Kostis
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Am J Cardiol 96:313-21. 2005..Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended...
Vardenafil--PDE5 inhibitor number 3Graham Jackson
Int J Clin Pract 58:229. 2004
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive menRobert A Kloner
The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
J Urol 172:1935-40. 2004..We examined the hemodynamic interactions of tadalafil with the alpha-blockers doxazosin and tamsulosin...
Time course of the interaction between tadalafil and nitratesRobert A Kloner
The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
J Am Coll Cardiol 42:1855-60. 2003..This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h...
Letter regarding article by Gazzaruso et al, "Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated, type 2 diabetic patients"Graham Jackson
Circulation 111:e18-9; author reply e18-9. 2005
PDE5 inhibitors: looking beyond EDGraham Jackson
Int J Clin Pract 57:159-60. 2003
Sildenafil (Viagra): new data, new confidence in treating erectile dysfunction in the cardiovascular patientGraham Jackson
Int J Clin Pract 56:75. 2002
Phosphodiesterase inhibition: erectile dysfunction is only part of the storyGraham Jackson
Int J Clin Pract 56:236. 2002
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular diseaseHunter C Gillies
Clinical Development, Pfizer Global Research and Development, Ramsgate Road, Kent CT13 9NJ, Sandwich, UK
Int J Cardiol 86:131-41. 2002..Finally, exciting reports have emerged from clinical experience with the use of phosphodiesterase type 5 inhibitors in patients with pulmonary hypertension...
Erectile dysfunction and vascular risk: Let's get it rightGraham Jackson
Eur Urol 50:660-1. 2006
Should erectile dysfunction be treated as secondary prevention for coronary disease?Graham Jackson
Int J Clin Pract 60:1335. 2006
The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and preventionRaymond C Rosen
Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, NJ, USA
J Sex Med 3:960-75; discussion 973-5. 2006..Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals...
The cardiac urologistGraham Jackson
Int J Clin Pract 61:181-2. 2007
Stable angina--medical therapy gives us time to optimise managementGraham Jackson
Int J Clin Pract 58:107-8. 2004
Ranolazine--a nicely timed new medical therapy for stable anginaGraham Jackson
Int J Clin Pract 61:1063. 2007
Giving up smokingGraham Jackson
Hosp Med 65:134-5. 2004
Women and heart disease: a British Heart Foundation initiativeGraham Jackson
Int J Clin Pract 57:75. 2003
Smoking: suicide for some, manslaughter for others--time for a ban in all public placesGraham Jackson
Int J Clin Pract 58:1. 2004
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 studySylvia Feyler
St James University Hospital, Leeds, UK
Br J Haematol 139:429-33. 2007..5 months. Maintenance doses >200 mg were largely unachievable and peripheral neuropathy was the main toxicity. Lower doses enabled more patients to stay on the drug for a useful period of time...
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trialPatrick W J C Serruys
Interventional Cardiology, Thoraxcenter, Bd 418, Academic Hospital, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
JAMA 287:3215-22. 2002....
Hypertension: treating the patient as well as the blood pressureGraham Jackson
Int J Clin Pract 57:357. 2003
A male cardiovascular sexual health clinicGraham Jackson
Int J Clin Pract 56:631. 2002
Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by plateletsPeter D O'Kane
Department of Clinical Pharmacology, Cardiovascular Division, 3 07 Franklin Wilkins Building, King s College London, 150 Stamford Street, London SE1 9NH, UK
J Mol Cell Cardiol 45:223-9. 2008..Moreover, CHD may itself be associated with decreased platelet NO biosynthesis...
Believe-it then PROVE-ITGraham Jackson
Int J Clin Pract 58:325-6. 2004
Endothelial function and dysfunctionGraham Jackson
Int J Clin Pract 58:431. 2004
Prevention of disease--education makes a difference in the communityGraham Jackson
Int J Clin Pract 59:263. 2005
Pharmacotherapy for erectile dysfunctionHarin Padma-Nathan
J Sex Med 1:128-40. 2004..Advances in understanding of the biochemistry and physiology of penile erection have led to breakthroughs in pharmacotherapy of erectile dysfunction...
Erectile dysfunction, like diabetes, should be considered a 'cardiovascular equivalent'Graham Jackson
Int J Clin Pract 59:507. 2005
Lipids and cardiovascular risk reduction -- new targets, new challengesGraham Jackson
Int J Clin Pract 59:617-8. 2005
Erectile dysfunction: the need to be evaluated, the right to be treatedHemant Solomon
Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN 55905, USA
Am Heart J 150:620-6. 2005..Specific guidelines for the management of ED in cardiac patients, produced by 2 expert panels, can also be applied to men without known cardiovascular disease...
"Oh ... by the way ... ": doorknob syndromeGraham Jackson
Int J Clin Pract 59:869. 2005
Blood pressure lowering--is degree more important than method?Graham Jackson
Int J Clin Pract 59:995-7. 2005
PDE 5 inhibitors and HIV risk: current concepts and controversiesGraham Jackson
Int J Clin Pract 59:1247-8. 2005
Safety and compliance of intravenous and oral dosing regimensGraham Jackson
Oncologist 10:313-4; author reply 315-6. 2005
DenialGraham Jackson
Int J Clin Pract 60:253. 2006
Primary angioplasty in acute myocardial infarction - the preferred option, but time is of the essenceGraham Jackson
Int J Clin Pract 60:379. 2006
Smoking politicsGraham Jackson
Int J Clin Pract 58:649. 2004
Testosterone - not just a replacement therapyGraham Jackson
Int J Clin Pract 60:1021-2. 2006
Erectile dysfunction: a management algorithmGraham Jackson
Int J Clin Pract 58:733-4. 2004
Diabetic and hypertension guidelines updatedGraham Jackson
Int J Clin Pract 58:815-6. 2004..No risk factor should be managed in isolation--overall risk reduction is essential. We have a job to do and must do it thoroughly--we now need a programme of early detection and that needs political will and investment...
Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosisGraham Jackson
Int J Clin Pract 60:891-2. 2006
Erectile dysfunction: a marker of silent coronary artery diseaseGraham Jackson
Eur Heart J 27:2613-4. 2006
Sexual medicine society of North AmericaGraham Jackson
Int J Clin Pract 60:759-60. 2006
The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadismGraham Jackson
Eur Urol 50:426-7. 2006
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trialKausik K Ray
TIMI Study Group, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 46:1405-10. 2005..In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy...
